RecruitingPHASE1, PHASE2NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Essen Biotech
- Intervention
- CD19/CD22-CAR T cells(biological)
- Enrollment
- 75 enrolled
- Eligibility
- 2-90 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- District One Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06213636 on ClinicalTrials.gov